GALAPAGOS NV NPV ISIN BE0003818359 SEDOL B07Q2V5 GLPGF
COMMONSTOCK · Common Stock · CUSIP B44170106
Belgian pharmaceutical company
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $196.61.
Trends to Q2 2020
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2019 | 1 |
| Q1 2020 | 1 |
| Q2 2020 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2020 | 0 | 1 |
| Q2 2020 | 0 | 1 |
Biggest buyers
| None |
Biggest sellers
| GILDER GAGNON HOWE & CO LLC | Reduced | -366.6k |
Insider purchases and sales in Q2 2020
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2020.
Holders, Q2 2020
| Manager | Shares | Change |
|---|---|---|
| GILDER GAGNON HOWE & CO LLC 0.44% of their portfolio | 286.5k $56.3m | Reduced -366.6k |